Maybe a New Target for Gli̇omas: AQP1

Abstract

Abstract Backround: Gliomas, which are the most common tumors of the central nervous system, are also among the most aggressive tumors. Despite the studies, the prognosis of gliomas is poor. Therefore, studies that will form the basis for the diagnosis and treatment of the disease are very important for these patient groups. In this study, the course of members of the Aquaporin family in gliomas was examined, and among these, the relationship of AQP1 and AQP4 with gliomas was investigated. Methods and Results: In this study conducted using in silico methods, the expression levels of the AQP family in LGG and GBM-type gliomas were compared. As a result of the findings obtained here, the prognostic value and clinical importance of AQP1 and AQP4 were evaluated. For this purpose, GEPIA, UCSC Xena, Gliovis, cBioPortal, and Ivy GAP analysis tools were used. According to the data obtained at the end of the study, AQP1 and AQP4 gene expressions were found to be more expressed in tumor tissue than in normal tissue in the LGG and GBM datasets. Thereupon, the effects of these two genes on the survival and prognosis of patients were investigated using the expression patterns in the LGG and GBM datasets. When the expression levels of these two genes were compared in the subtypes, it was found that AQP1 was low in the Oligodendrogram subtype of LGG, and both AQP1 and AQP4 levels were high in all the remaining subtypes. Conclusions: Within the framework of the findings, it can be said that not only AQP4 but also AQP1 from the aquaporin family is one of the genes effective in the pathogenesis of gliomas and patient survival. AQP1 may be used as a new drug target or biomarker against aggressive gliomas. Therefore, it should be evaluated for future studies.